- 68Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomographic (PET) imaging showed high positive predictive value (PPV), detection rate, and interreader agreement in patients with biochemically recurrent prostate cancer.
- No grade ≥2 adverse events were reported.
Why this matters
- This study confirms utility of 68Ga-PSMA-11 PET screening in early detection of metastases observed in prior retrospective studies.
- Prospective, multicenter study.
- 635 patients with recurrent prostate cancer received 68Ga-PSMA-11 PET imaging.
- Funding: None disclosed.
- PPV was 0.84 for tumor on a per patient and per region basis (95% CI, 0.75-0.90 and 0.76-0.91, respectively).
- Overall PET detection rate was 75%.
- Detection rate was significantly high across predefined PSA ranges:
- Interreader agreement was substantial for all 4 regions: κ: prostate bed, 0.65; pelvic nodes, 0.73; extrapelvic soft tissue, 0.70; bone, 0.78.
- No grade ≥2 adverse events were reported; 2% patients experienced grade 1 toxicities.
- After PET-directed focal therapy, 80% of 39 patients experienced PSA decline of ≥50%.
- Single-group study.